Keywords: Ipsen, Increlex, research

Ipsen reveals positive findings with rhGH and Increlex

Article | 16 September 2009

Print This

France’s Ipsen has announced preliminary results from a Phase II open-label clinical trial (MS316 study) that evaluates the co-administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in